Company news
Revolution Medicines, Inc. (NASDAQ:RVMD) news
Every Revolution Medicines, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates
July 9, 2025
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
June 30, 2025
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors
June 30, 2025
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers
June 24, 2025
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations
June 23, 2025
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer
May 14, 2025
Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress
May 7, 2025
Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025
April 30, 2025
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting
April 27, 2025
Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
April 1, 2025
Revolution Medicines to Participate in April 2025 Investor Conferences
March 31, 2025
Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress
February 26, 2025
Revolution Medicines to Participate in March 2025 Investor Conferences
February 24, 2025
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025
February 19, 2025
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference
January 29, 2025
Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
December 5, 2024
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
December 3, 2024
Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio
December 2, 2024
Revolution Medicines Announces Commencement of Public Offering of Common Stock
December 2, 2024
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
November 27, 2024
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
November 6, 2024
Revolution Medicines to Participate in Upcoming Investor Conferences
November 5, 2024
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
October 30, 2024
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
October 25, 2024
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
October 23, 2024
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
October 21, 2024
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
October 7, 2024
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
August 7, 2024
Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024
July 31, 2024
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
July 11, 2024
Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024
July 8, 2024
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
June 5, 2024
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
May 8, 2024
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
May 1, 2024
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
April 9, 2024
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
April 8, 2024
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
March 28, 2024
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
February 26, 2024
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
February 20, 2024
Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 4, 2024
Revolution Medicines Completes Acquisition of EQRx
November 9, 2023
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition
November 8, 2023
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
November 6, 2023
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.
November 1, 2023
Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023
October 31, 2023
Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236
October 22, 2023
Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting
October 13, 2023
Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
October 4, 2023
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
September 19, 2023